Julie M. Porter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julie M. Porter has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Ernest Ayers
Division of Nephrology, University of Washington, Seattle, Washington
2 shared publications - Matthew B. Rivara
Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington
2 shared publications - Nisha Bansal
Department of Medicine, University of Washington, Seattle, Washington
2 shared publications - Rajnish Mehrotra
University of Washington
2 shared publications - Andrew N. Hoofnagle
Department of Laboratory Medicine & Pathology, University of Washington , Seattle, WA
1 shared publication Anne Pesenson
Northwest Kidney Centers, Seattle, Washington
1 shared publication
Latest Publications
- 27 October 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (1) , 141-143
A Qualitative Study of Nephrologists' Perceptions of Management of Hypertension in Hemodialysis Patients
- 27 October 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (1) , 141-143
A Qualitative Study of Nephrologists' Perceptions of Management of Hypertension in Hemodialysis Patients
- 21 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1798-1810
Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis
Key Points: In maintenance dialysis, continuous glucose monitoring frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. Patients with treated diabetes rarely met contemporary continuous glucose monitoring–based treatment targets. Background: Kidney failure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but published studies in kidney failure are limited to small, select groups. We aimed to characterize the spectrum of glycemia and its determinants in a large, diverse maintenance dialysis population. Methods: We conducted a prospective community-based cohort study of people treated with maintenance dialysis. Each participant wore a Dexcom G6 Pro CGM for approximately 10 days. Outcomes ascertained by CGM included mean blood glucose, time in range (TIR, 70–180 mg/dl), and hypoglycemia events (sustained P < 0.001). Among participants with untreated diabetes, the mean blood glucose was 162 mg/dl, mean TIR 71%, and only 64% of participants attained TIR ≥70%, while mean hemoglobin A1c (HbA1c) was 5.7%. Among participants with treated diabetes, the mean blood glucose was 214 mg/dl, the mean TIR was 43%, and only 22% of participants attained TIR ≥70%, while the mean HbA1c was 7.0%. In total, 714 unique sustained hypoglycemia events were observed, with highest rates for participants without diabetes. In addition to diabetes and dialysis modality, age, dialysis vintage, insulin use, HbA1c, and serum albumin were significantly associated with mean blood glucose, hypoglycemia, or both. Conclusions: In maintenance dialysis, CGM frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. In particular, hyperglycemia was common with PD, patients with untreated diabetes maintained a diabetic glycemic profile, and patients with treated diabetes rarely met contemporary CGM-based treatment targets.
- 21 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1798-1810
Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis
Key Points: In maintenance dialysis, continuous glucose monitoring frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. Patients with treated diabetes rarely met contemporary continuous glucose monitoring–based treatment targets. Background: Kidney failure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but published studies in kidney failure are limited to small, select groups. We aimed to characterize the spectrum of glycemia and its determinants in a large, diverse maintenance dialysis population. Methods: We conducted a prospective community-based cohort study of people treated with maintenance dialysis. Each participant wore a Dexcom G6 Pro CGM for approximately 10 days. Outcomes ascertained by CGM included mean blood glucose, time in range (TIR, 70–180 mg/dl), and hypoglycemia events (sustained P < 0.001). Among participants with untreated diabetes, the mean blood glucose was 162 mg/dl, mean TIR 71%, and only 64% of participants attained TIR ≥70%, while mean hemoglobin A1c (HbA1c) was 5.7%. Among participants with treated diabetes, the mean blood glucose was 214 mg/dl, the mean TIR was 43%, and only 22% of participants attained TIR ≥70%, while the mean HbA1c was 7.0%. In total, 714 unique sustained hypoglycemia events were observed, with highest rates for participants without diabetes. In addition to diabetes and dialysis modality, age, dialysis vintage, insulin use, HbA1c, and serum albumin were significantly associated with mean blood glucose, hypoglycemia, or both. Conclusions: In maintenance dialysis, CGM frequently identified both hyperglycemia and hypoglycemia that may not be clinically evident. In particular, hyperglycemia was common with PD, patients with untreated diabetes maintained a diabetic glycemic profile, and patients with treated diabetes rarely met contemporary CGM-based treatment targets.